L
Laure Y. Juompan
Researcher at Walter Reed Army Institute of Research
Publications - 9
Citations - 914
Laure Y. Juompan is an academic researcher from Walter Reed Army Institute of Research. The author has contributed to research in topics: Malaria vaccine & Antigen. The author has an hindex of 8, co-authored 9 publications receiving 854 citations.
Papers
More filters
Journal ArticleDOI
Randomized, Double-Blind, Phase 2a Trial of Falciparum Malaria Vaccines RTS,S/AS01B and RTS,S/AS02A in Malaria-Naive Adults: Safety, Efficacy, and Immunologic Associates of Protection
Kent E. Kester,James F. Cummings,Opokua Ofori-Anyinam,Christian F. Ockenhouse,Urszula Krzych,Philippe Moris,Robert Schwenk,Robin Nielsen,Zufan Debebe,Evgeny Pinelis,Laure Y. Juompan,Jack Williams,Megan Dowler,V. Ann Stewart,Robert A. Wirtz,Marie-Claude Dubois,Marc Lievens,Joe Cohen,W. Ripley Ballou,D. Gray Heppner +19 more
TL;DR: The R TS,S/AS01B malaria vaccine warrants comparative field trials with RTS,S /AS02A to determine the best formulation for the protection of children and infants.
Journal ArticleDOI
Phase 1/2a Study of the Malaria Vaccine Candidate Apical Membrane Antigen-1 (AMA-1) Administered in Adjuvant System AS01B or AS02A
Michele D. Spring,James F. Cummings,Christian F. Ockenhouse,Sheetij Dutta,Randall Reidler,Evelina Angov,Elke S. Bergmann-Leitner,V. Ann Stewart,Stacey Bittner,Laure Y. Juompan,Mark G. Kortepeter,Robin Nielsen,Urszula Krzych,Ev Tierney,Lisa A. Ware,Megan Dowler,Cornelus C. Hermsen,Robert W. Sauerwein,Sake J. de Vlas,Opokua Ofori-Anyinam,David E. Lanar,Jack Williams,Kent E. Kester,Kathryn Tucker,Meng Shi,Elissa Malkin,Carole A. Long,Carter L. Diggs,Lorraine Soisson,Marie-Claude Dubois,W. Ripley Ballou,Joe Cohen,D. Gray Heppner +32 more
TL;DR: All three vaccine formulations were found to be safe and highly immunogenic and immune responses did not translate into significant vaccine efficacy in malaria-naïve adults employing a primary sporozoite challenge model, but encouragingly, estimation of parasite growth rates from qPCR data may suggest a partial biological effect of the vaccine.
Journal ArticleDOI
Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-γ/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection
James F. Cummings,Michele D. Spring,Robert Schwenk,Christian F. Ockenhouse,Kent E. Kester,Mark E. Polhemus,Douglas S. Walsh,In-Kyu Yoon,Christine Prosperi,Laure Y. Juompan,David E. Lanar,Urszula Krzych,B. Ted Hall,Lisa A. Ware,V. Ann Stewart,Jack Williams,Megan Dowler,Robin K. Nielsen,Collette J. Hillier,Birgitte Giersing,Filip Dubovsky,Elissa Malkin,Kathryn Tucker,Marie-Claude Dubois,Joe Cohen,W. Ripley Ballou,D. Gray Heppner +26 more
TL;DR: Although the optimal antigen dose of LSA-NRC may not have been selected for the challenge portion of the protocol, further vaccine development based upon L SA-1 should not be excluded and should include alternative vaccine platforms able to elicit additional effector mechanisms such as CD8+ T cells.
Journal ArticleDOI
Development of a cAdVax-Based Bivalent Ebola Virus Vaccine That Induces Immune Responses against both the Sudan and Zaire Species of Ebola Virus
Danher Wang,Nicholas U. Raja,Charles M. Trubey,Laure Y. Juompan,Min Luo,Jan Woraratanadharm,Stephen B. Deitz,Hong Yu,Benjamin M. Swain,Kevin M. Moore,William D. Pratt,Mary Kate Hart,John Y. Dong +12 more
TL;DR: The cAdVax technology demonstrated induction of a 100% protective immune response in mice, as all vaccinated C57BL/6 and BALB/c mice survived challenge with a lethal dose of ZEBOV.
Journal ArticleDOI
De novo syntheses of Marburg virus antigens from adenovirus vectors induce potent humoral and cellular immune responses.
Danher Wang,Alan L. Schmaljohn,Nicholas U. Raja,Charles M. Trubey,Laure Y. Juompan,Min Luo,Stephen B. Deitz,Hong Yu,Jan Woraratanadharm,David H. Holman,Kevin M. Moore,Benjamin M. Swain,William D. Pratt,John Y. Dong +13 more
TL;DR: Three novel gene-based vaccine candidates which express the viral glycoprotein (GP) from either the Ci67, Ravn or Musoke strain of MARV are developed and characterized, and promising results indicate that a cAdVax- based vaccine could be effective for induction of both humoral and cell-mediated immune responses to multiple strains of the Marburg virus.